Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), noting the company's progress from commissioning into early utilization at its Galesburg facility. With growing customer volume, Burcon is positioned for better fixed-cost absorption as production scales.
Burcon completed commissioning and launched commercial production across its Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein lines in fiscal year 2026. Revenue increased sequentially to $0.83 million in the fourth quarter of fiscal 2026 from $0.74 million in the third quarter, and management indicated that current-quarter sales were tracking toward approximately 50% sequential growth based on April and May activity. The company also set a new production record, with daily output roughly 60% above January–March levels.
As volume builds, the margin opportunity is expected to come from better utilization, a steadier production cadence, and start-up costs moving out of the run-rate cost structure, rather than pricing alone. Burcon has seen customer traction broaden, with over 30 purchasing customers and more than 200 active projects across pea, canola, and fava applications. Funding supports the Galesburg scale-up, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million of calendar year 2026 sales.
For more details, the full announcement is available here.
